Skip to main content

Advertisement

SpringerLink
Log in

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Gengler C, Guillou L (2006) Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 48(1):63–74. doi:10.1111/j.1365-2559.2005.02290.x Review

    Article  CAS  PubMed  Google Scholar 

  2. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Choi H, Benjamin RS, Araujo DM (2008) Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. J Clin Oncol 26:(May 20 suppl; abstr 10512)

  3. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25–35. doi:10.1200/JCO.2005.02.2194

    Article  CAS  PubMed  Google Scholar 

  4. DuBois S, Demetri G (2007) Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109(5):813–819. doi:10.1002/cncr.22455 Review

    Article  CAS  PubMed  Google Scholar 

  5. Balasubramanian L, Evens AM (2006) Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 18(4):354–359. doi:10.1097/01.cco.0000228741.64541.ca Review

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors thank Lorna Saint Ange for editing.

Author information

Authors and Affiliations

  1. Department of Medicine, Sarcoma Group, Institut Gustave Roussy, Villejuif, France

    Julien Domont & Axel Le Cesne

  2. Université Paris XI, SITEP (Service des Innovations Thérapeutiques Précoces), Département de Médecine, Institut Gustave Roussy, rue Camille-Desmoulins, 94805, Villejuif, France

    Christophe Massard, Jean-Pierre Armand & Jean-Charles Soria

  3. Imaging Department, Institut Gustave Roussy, Villejuif, France

    Nathalie Lassau

Authors
  1. Julien Domont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Massard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathalie Lassau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Pierre Armand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Axel Le Cesne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Charles Soria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Charles Soria.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Domont, J., Massard, C., Lassau, N. et al. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour. Invest New Drugs 28, 199–202 (2010). https://doi.org/10.1007/s10637-009-9249-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9249-1

Keywords

Search

Navigation